PMC9843526_01
The bone marrow (BM) trephine biopsy sample histopathological evaluation results in type 2 CALR mutation positive essential thrombocythemia patient developing multiple myeloma during disease outcome. Multiple myeloma cells immunophenotype: CD138++, MUM1+, CD56, CD20-, cyclin D1-, Ig-CISH-kappa+++/Ig-lambda-.
JCMM-27-299-g002.jpg
PMC9843526_01_JCMM-27-299-g002.jpg
jcmm17647-fig-0001
Retrospective analysis of a biopsy sample collected in 2020 (before PEG-INFalpha2a treatment initiation) confirmed the presence of a small, abnormal plasma cell population with the same immunophenotypic characteristic (Figure 1). T > G) and the wild type of CALR, JAK2 and MPL gene sequence (Figure S1). The analysis of the blood sample collected at the time of PEG-INF2alpha treatment initiation using the SS did not confirm the presence of the HRAS variant. The HRAS mutations were also undetectable in the DNA obtained from the blood MNC and buccal swab cells collected immediately before MM treatment initiation (Figure S1).
The changes in the basic laboratory parameters in a patient with type 2 CALR mutation positive essential thrombocythemia developing multiple myeloma during disease outcome. The timeline and treatment type are shown.
JCMM-27-299-g001.jpg
PMC9843526_01_JCMM-27-299-g001.jpg
jcmm17647-fig-0002
After three VTD therapy cycles, a significant reduction of the protein M concentration in the blood from 49.6 g/L to 3.6 g/L was confirmed (Figure 2).